UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (342) 342
science & technology (312) 312
life sciences & biomedicine (306) 306
antiviral agents - therapeutic use (275) 275
hepatitis c, chronic - drug therapy (236) 236
simeprevir (233) 233
drug therapy, combination (187) 187
hepatitis c (186) 186
male (186) 186
female (174) 174
middle aged (170) 170
hepacivirus - genetics (159) 159
simeprevir - therapeutic use (157) 157
hepatitis c virus (156) 156
ribavirin - therapeutic use (142) 142
gastroenterology & hepatology (141) 141
genotype (141) 141
sofosbuvir (137) 137
treatment outcome (127) 127
aged (117) 117
sofosbuvir - therapeutic use (101) 101
adult (99) 99
hepatitis c - drug therapy (96) 96
interferon (92) 92
sulfonamides - therapeutic use (91) 91
hepacivirus - drug effects (90) 90
hepatitis (87) 87
antiviral agents - adverse effects (86) 86
heterocyclic compounds, 3-ring - therapeutic use (80) 80
antiviral agents (76) 76
antiviral agents - administration & dosage (73) 73
interferon-alpha - therapeutic use (73) 73
ribavirin (73) 73
hepatitis c, chronic - virology (70) 70
pharmacology & pharmacy (69) 69
infectious diseases (64) 64
uridine monophosphate - analogs & derivatives (63) 63
biological response modifiers (61) 61
care and treatment (60) 60
health aspects (60) 60
liver (56) 56
liver transplantation (55) 55
hepatitis c, chronic - complications (54) 54
polyethylene glycols - therapeutic use (54) 54
simeprevir - adverse effects (54) 54
analysis (52) 52
drug therapy (51) 51
transplantation (51) 51
protease inhibitors - therapeutic use (50) 50
uridine monophosphate - therapeutic use (50) 50
simeprevir - administration & dosage (49) 49
sustained virologic response (48) 48
liver cirrhosis (47) 47
genetic aspects (46) 46
imidazoles - therapeutic use (45) 45
recombinant proteins - therapeutic use (45) 45
protease inhibitors (43) 43
daclatasvir (42) 42
recurrence (42) 42
ribavirin - administration & dosage (42) 42
ribavirin - adverse effects (40) 40
sofosbuvir - administration & dosage (36) 36
hepatitis c - virology (35) 35
patients (35) 35
viral load (35) 35
antiviral agents - pharmacology (34) 34
viral nonstructural proteins - antagonists & inhibitors (34) 34
gastroenterology and hepatology (33) 33
retrospective studies (33) 33
virology (33) 33
genotype & phenotype (32) 32
hepatology (32) 32
infections (32) 32
young adult (32) 32
hepacivirus - isolation & purification (31) 31
antiviral agents - economics (30) 30
cirrhosis (30) 30
direct-acting antivirals (30) 30
liver cirrhosis - drug therapy (30) 30
sofosbuvir - adverse effects (30) 30
telaprevir (30) 30
abridged index medicus (28) 28
benzimidazoles - therapeutic use (28) 28
fluorenes - therapeutic use (28) 28
liver cirrhosis - virology (28) 28
oligopeptides - therapeutic use (28) 28
proteases (28) 28
general & internal medicine (27) 27
hcv (27) 27
medicine, general & internal (27) 27
microbiology (27) 27
surgery (27) 27
hepatitis c, chronic - diagnosis (26) 26
medicine & public health (26) 26
chronic hepatitis c (25) 25
hepacivirus (25) 25
immunology (25) 25
ledipasvir (25) 25
viruses (25) 25
drug interactions (24) 24
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (362) 362
German (6) 6
French (3) 3
Japanese (3) 3
Portuguese (3) 3
Hungarian (2) 2
Polish (2) 2
Russian (2) 2
Spanish (2) 2
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European journal of gastroenterology & hepatology, ISSN 0954-691X, 11/2019, Volume 31, Issue 11, pp. 1424 - 1431
Journal Article
BMC gastroenterology, ISSN 1471-230X, 08/2015, Volume 15, Issue 1, pp. 98 - 98
Journal Article
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 4/2014, Volume 58, Issue 7, pp. 928 - 936
Antiretrovirals | HIV | Cost estimates | Antivirals | Raw material costs | Raw materials | ARTICLES AND COMMENTARIES | Hepatitis C | Dosage | Hepacivirus | Production costs | sofosbuvir | faldaprevir | ribavirin | simeprevir | daclatasvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Antiviral agents | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Heterocyclic Compounds, 3-Ring - economics | Simeprevir | Oligopeptides - economics | Hepatitis C - drug therapy | Ribavirin - economics | Humans | Imidazoles - chemistry | Uridine Monophosphate - chemistry | Uridine Monophosphate - economics | Thiazoles - therapeutic use | Health Services Accessibility - economics | Oligopeptides - therapeutic use | Antiviral Agents - chemistry | Drug Industry - economics | Imidazoles - therapeutic use | Drug Therapy, Combination | Oligopeptides - chemistry | Thiazoles - economics | Uridine Monophosphate - therapeutic use | Sulfonamides - chemistry | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Ribavirin - chemistry | Anti-HIV Agents - chemistry | Sulfonamides - therapeutic use | Imidazoles - economics | Heterocyclic Compounds, 3-Ring - chemistry | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Thiazoles - chemistry | Developing Countries | Antiviral Agents - economics | Sofosbuvir | Economic aspects | Production management | Care and treatment | Hepatitis | Antiviral drugs | Medical treatment | Developing countries--LDCs | Index Medicus | and Commentaries
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 146, Issue 2, pp. 430 - 441.e6
Journal Article
Tropical medicine & international health, ISSN 1360-2276, 12/2016, Volume 21, Issue 12, pp. 1490 - 1495
Parasitology | Quality of medicines | Infectious Diseases | Public Health, Environmental and Occupational Health | Hepatitis C | Counterfeit medicines | Access to medicines | Substandard medicines | Essential medicines | substandard medicines | essential medicines | quality of medicines | access to medicines | hepatitis C | counterfeit medicines | Public, Environmental & Occupational Health | Life Sciences & Biomedicine | Science & Technology | Tropical Medicine | Anilides - therapeutic use | Drug Industry - legislation & jurisprudence | Humans | Fluorenes - therapeutic use | Quality Assurance, Health Care - legislation & jurisprudence | Quality Assurance, Health Care - economics | Simeprevir - therapeutic use | Health Services Accessibility - economics | Drug Industry - economics | Ritonavir - therapeutic use | Imidazoles - therapeutic use | Benzimidazoles - therapeutic use | Quality Control | Uridine Monophosphate - therapeutic use | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Drug Therapy, Combination - economics | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - economics | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Uridine Monophosphate - analogs & derivatives | Public Health - trends | Fees, Pharmaceutical | Antiviral Agents - economics | Carbamates - therapeutic use | Uracil - analogs & derivatives | Drugs | Health aspects | Public health | Drug counterfeiting | Index Medicus
Journal Article